research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
Search
for
Sort by
Research
930-960 / 1000+ results research Improved 2α-Hydroxylation Efficiency of Steroids by CYP154C2 Using Structure-Guided Rational Design
Mutants of CYP154C2 enzyme significantly improved steroid conversion efficiency.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Retrospektive Analyse von Wirksamkeit, Sicherheit, prognostischen Parametern und Faktoren der Lebensqualität bei der topischen Immuntherapie der Alopecia areata mit Diphenylcyclopropenon
Diphenylcyclopropenon treatment for Alopecia areata is effective and safe, improving patients' quality of life.
research PHOSPHATIDES IN MOUSE EPIDERMIS UNDERGOING NORMAL AND ABNORMAL GROWTH CHANGES.
Phosphatide distribution in mouse skin remains consistent in both normal and cancerous growths.
research Dermoscopic evaluation of therapeutic response to intralesional triamcinolone acetonide in the treatment of Alopecia areata
Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application
Improved finasteride formula allows slow, sustained release and better absorption for patients.
research Bimatoprost
research Clinical uses for calciotropic hormones 1,25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology: a new perspective.
Vitamin D3 and parathyroid hormone-related peptide may have important uses in skin treatments.
research Dermatoloji Polikliniğine Başvuran Hastaların Geleneksel ve Tamamlayıcı Tıp Uygulamaları
Some dermatology patients use traditional and complementary medicine, often for acne, and many recommend it, but they need more information about its effects.
research Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
research Isolated hyperthermic chemotherapy perfusion for limb melanoma is a safe procedure
Isolated hyperthermic chemotherapy perfusion for limb melanoma is safe and effective with manageable side effects.
research Atrichia with papular lesions
Accurate diagnosis of APL is crucial to avoid unnecessary treatments.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research MICROBIAL OXIDATION OF FINASTERIDE WITH MACROPHOMINA PHASEOLINA(KUCC 730)
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Successful Treatment of Lichen Spinulosus with Topical Tacalcitol Cream
Tacalcitol cream effectively and safely treated a rare skin condition called Lichen Spinulosus in two cases.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Expanding the therapeutic versatility of clacosterone
Clascoterone cream could be used for other skin conditions affected by hormones.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
research Cyproterone acetate as initial treatment and maintenance therapy for hirsutism
Cyproterone acetate is effective for treating hirsutism, but some patients may feel worse on low-dose maintenance therapy.
research A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy
Tempol is safe and may prevent hair loss from brain radiotherapy.
research An Innovative Formula for Keratosis Pilaris Treatment—A Randomized Controlled Study Based on the “Exfoliation‐Dissolution‐Repair” Concept
The new treatment improved keratosis pilaris symptoms and mood in 28 days.
research Topical calcipotriol mixed with topical steroid versus topical steroid alone in treatment of alopecia areata
Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.
research Baricitinib in the Management of Coexisting Alopecia Areata and Atopic Dermatitis: A Case Report
Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.